ArticleInternational journal of nanomedicine2025
Optimized Lipid Nanoparticle-Mediated mRNA Co-Delivery of SOX5/SOX9 Enables Synergistic Senescence Reversal for Osteoarthritis Therapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chondrocyte senescence significantly impairs extracellular matrix (ECM) synthesis and accelerates cartilage degradation, driving osteoarthritis (OA) progression. Although gene therapies targeting senescent chondrocytes are promising for OA, developing strategies that simultaneously rejuvenate cartilage function and precisely modulate the inflammatory microenvironment remains challenging. Methods: We developed an optimized lipid nanoparticle (LNP)-based delivery platform for the efficient co-delivery of transcription factors SOX5 and SOX9 mRNAs into chondrocytes. The physicochemical properties and biosafety of the formulations were systematically characterized. Additionally, the therapeutic efficacy of these formulations was evaluated in senescent chondrocyte cultures and an ACLT-induced osteoarthritis (OA) rat model. Results: The synergistic action of SOX5 and SOX9 markedly enhanced anabolic signaling, promoting synthesis of critical cartilage ECM components (type II collagen and aggrecan). The combination also reduced inflammation-mediated matrix degradation in vitro and in vivo. In a rat OA model, this optimized LNP-mediated co-delivery substantially improved cartilage regeneration, suppressed joint inflammation, and restored joint function compared to single-gene treatment or untreated controls. Conclusion: This work provides an advanced, synergistic mRNA therapeutic approach employing optimized LNPs to alleviate chondrocyte senescence and stimulate cartilage regeneration, representing a promising strategy for OA intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.